Mannose Receptor C type 2 influences autoimmune neuroinflammation and blood-brain barrier integrity
Preprint
- 7 July 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Relapses in Multiple Sclerosis (MS) are driven by pathogenic immune cells breaching the disrupted blood–brain barrier (BBB), leading to tissue damage and eventual disease progression1–3. Among the most effective therapies are those that block immune cell infiltration across the BBB, a multistep process involving activation, adhesion, rolling, transendothelial migration, and extracellular matrix (ECM) degradation. Current treatments broadly suppress the immune system and can cause adverse side effects4,5, highlighting the need for targeted approaches. Here, we identified a previously unrecognized role of ECM remodeling pathways and Mannose Receptor C-type 2 (MRC2) in invasive T lymphocytes as a potential therapeutic target. Typically low under physiological conditions, MRC2 was upregulated on T lymphocytes upon inflammatory stimulation in vitro, enriched in the periphery of MS patients during relapse and progressive disease, and present in cerebrospinal fluid and active brain lesions co-localized with Col IV, the major ECM component of the BBB. Genetic deletion of MRC2 impaired T lymphocyte-mediated Col IV degradation, adhesion, and transendothelial migration, and leading to reduced neuroinflammation in a sex-dependent manner in an MS-like mouse model. These findings suggest MRC2 as a key regulator of T lymphocyte infiltration into the CNS and a promising target for MS therapy.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapiesThe Lancet Neurology, 2023
- Multiple sclerosis progression: time for a new mechanism-driven frameworkThe Lancet Neurology, 2022
- How patients with multiple sclerosis acquire disabilityBrain, 2022
- 1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosisCell Death & Disease, 2016
- Melanoma cell adhesion molecule–positiveCD8Tlymphocytes mediate central nervous system inflammationAnnals of Neurology, 2015
- Interendothelial Claudin-5 Expression Depends on Cerebral Endothelial Cell–Matrix Adhesion by β1-IntegrinsJournal of Cerebral Blood Flow & Metabolism, 2011
- Preferential recruitment of interferon‐γ–expressing TH17 cells in multiple sclerosisAnnals of Neurology, 2009
- Extensive extracellular matrix depositions in active multiple sclerosis lesionsNeurobiology of Disease, 2006
- Immune surveillance in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2006
- The Urokinase Receptor Associated Protein (uPARAP/Endo180) A Novel Internalization Receptor Connected to the Plasminogen Activation SystemTrends in Cardiovascular Medicine, 2001